Pegasys® (peginterferon alfa-2a) is a medication licensed for the treatment of chronic hepatitis B and C infections. It comes in the form of an injection that is given once a week just under the skin (subcutaneously) for 24 to 48 weeks. It is approved for treating hepatitis C in adults and children as young as five years old, and for hepatitis B in adults only.
While some people may not have any problems with this drug, most people will develop some type of side effect. Some of the most commonly reported problems include headaches, fatigue, and fever.
Before using Pegasys, make sure your healthcare provider has up-to-date information on any other drugs you are taking, including vitamins and supplements, as well as any allergies you may have, including to medications, foods, dyes, or preservatives. Also, let your healthcare provider know if you have certain medical issues, such as lung problems, diabetes, or depression.
(For more information, click Pegasys. This article provides information on how this drug works, dosing guidelines, and general safety precautions to be aware of before beginning treatment.)
Written by/reviewed by: Arthur Schoenstadt, MD
Last reviewed by: ArthurSchoenstadt, MD
List of references (click here):
Pegasys [package insert]. South San Francisco, CA: Genentech USA, Inc.;2011 September.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2008.
National Library of Medicine (US). Drugs and Lactation Database (LactMED). NLM Web site. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. Accessed December 5, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click